Recursion Pharmaceuticals (RXRX) Retained Earnings (2020 - 2026)

Recursion Pharmaceuticals' Retained Earnings history runs 7 years deep, the most recent figure standing at -$2.2 billion for Q1 2026.

• Quarterly Retained Earnings fell 34.66% year-over-year to -$2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 34.66% YoY) and the FY2025 annual result came in at $36.7 million, down 98.52% from the prior year.
• Retained Earnings was -$2.2 billion for Q1 2026 at Recursion Pharmaceuticals, down from $36.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $2.5 billion in Q4 2024 and bottomed at -$2.2 billion in Q1 2026.
• A 5-year average of -$85.6 million and a median of -$211.0 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings surged 893242.86% — and 2025, when it tumbled 211.89%.
• Recursion Pharmaceuticals' Retained Earnings stood at $1.1 billion in 2022, then rose by 16.64% to $1.3 billion in 2023, then soared by 88.46% to $2.5 billion in 2024, then plunged by 98.52% to $36.7 million in 2025, then slumped by 6091.77% to -$2.2 billion in 2026.
• Business Quant data shows RXRX's Retained Earnings at -$2.2 billion in Q1 2026, $36.7 million in Q4 2025, and $34.1 million in Q3 2025.